This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
partially because its key riskfactor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heart attack or stroke. Eighty percent of heart attacks and strokes are preventable. Yet, CVD remains the leading cause of death in the U.S.,
Getty Images milla1cf Fri, 06/28/2024 - 08:10 June 27, 2024 — Cardiovasculardisease is the leading cause of death for women, and gaps in care and access persist between women and men. Addressing those gaps could lead to an increase of at least 1.6 million years of quality life and boost the U.S.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. fold higher risk for cardiac mortality and 5.5-fold
Recently, the use of assisted reproductive technology (ART) has rapidly increased. Moreover, emerging evidence suggests an increased risk of cardiovasculardisease (CVD) in offspring conceived using ART. As a result, an increasing number of people are concerned about the safety of offspring produced through ART.
However, conversations are ongoing around best practices and standards of care regarding contrast management and treatment for those with higher riskfactors, like compromised renal function. Determine incidence of disease along with long term patient and economic implications.
The use of assisted reproductive technology (ART) is growing, both to assist individuals with infertility and for fertility preservation. Individuals with cardiovasculardisease (CVD), or riskfactors for CVD, are increasingly using ART. Circulation, Ahead of Print.
Kolossváry added, “The PRE-VUE registry will empower us to see the true additive value of CT-derived, histologically validated plaque volumes in predicting future adverse cardiovascular events.” 2017 23, April 2020; Available from: [link]. Hafiane, Vulnerable plaque, characteristics, detection, and potential therapies , J.
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
We will use modern technologies to explore the great number of chemicals in the food supply. We will then be able to identify among them new ‘natural’ therapies for heart disease for the health of all people.” We have a huge need to figure out how these genes are working together to promote, or protect, heart disease,” Rader said. “By
Here’s what you can expect at the biggest conference in cardiorenal metabolic health, the 19th Annual Cardiometabolic Congress (CMHC), DECODING THE CONSTELLATION of Cardiometabolic Health and RiskFactors. Learn more or secure your registration by clicking here.
HeartRisk combines insights from HIPAA-compliant anonymized and aggregated clinical cardiovascular data obtained through Cardio Diagnostics’ Epi+Gen CHD and PrecisionCHD clinical tests, with industry and geographic data to enable real-time population-level cardiovasculardisease (CVD) risk insights.
mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We
An overview of findings, presented by the Menlo Park, CA-based company, which offers a cardiovascular digital health program, follows. Validated in peer-reviewed studies, Hello Heart users achieve significant reductions in blood pressure and other cardiovascularriskfactors over a sustained period.
Understanding CardiovascularDisease in Women Understanding cardiovasculardisease in women involves recognizing unique riskfactors such as hormonal changes and pregnancy-related complications, necessitating proactive care and awareness to manage and prevent heart disease effectively.
However, conversations are ongoing around best practices and standards of care regarding contrast management and treatment for those with higher riskfactors, like compromised renal function. Determine incidence of disease along with long term patient and economic implications.
These patients also faced a 65% higher mortality rate, even after adjusting for traditional riskfactors. These findings underscore the power of AI-ECG in identifying patients at a significantly higher risk of MACE and mortality, even when traditional markers like left ventricular ejection fraction appear normal. Nicholas S.
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovasculardisease, type 2 diabetes, and metabolic syndrome. This ensures clear communication and identifies areas that need further explanation.
World Heart Day World Heart Day was established by the World Heart Federation to raise awareness about cardiovasculardiseases (CVD) and promote heart-healthy lifestyles. Cardiovasculardiseases remain the leading cause of death globally.
In the ever-evolving landscape of medical diagnostics, early disease detection stands as a critical frontier, offering the potential to save countless lives and improve patient outcomes. At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight.
In the ever-evolving landscape of medical diagnostics, early disease detection stands as a critical frontier, offering the potential to save countless lives and improve patient outcomes. At the forefront of this quest lie the remarkable advancements in imaging technology, ushering in a new era of precision and insight.
Cardiovasculardisease remains a leading cause of mortality worldwide. million people in the United States currently have one or more forms of cardiovasculardisease (CVD). Due to the prevalence of cardiovasculardisease, there are continuous advancements in cardiac surgery techniques.
However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovasculardisease also. Very low levels of desmosterol, a cholesterol synthesis marker, are often lower in those with Alzheimer’s dementia, and these low levels could be seen as a riskfactor for this condition 9.
Health and time have always been two sides of the same coin, but we haven’t had the technology to bridge them until now. COSMOS tested a cocoa extract supplement and a multivitamin-mineral supplement against one another and a placebo for reducing the risk of cardiovasculardisease and cancer.
Getty Images milla1cf Thu, 01/25/2024 - 20:44 January 25, 2024 — Agepha Pharma , a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment ( LODOCO – colchicine, 0.5 mg tablets for therapeutic intervention. mg tablets.”
Retired NFL players Joel Dreessen and Le-Lo Lang will be among the first individuals in the registry to receive a coronary artery disease (CAD) assessment with HeartFlows AI-driven technology. HeartFlows AI-driven technologies have helped healthcare providers diagnose CAD and guide treatment decisions for more than 400,000 patients.
The hypothesis that a raised cholesterol level causes heart disease [atherosclerotic cardiovasculardisease (ASCVD)] is possibly the single most powerful idea in medicine. Which remains the single most influential study on cardiovasculardisease, ever. At least some of it. It was simply a matter of time.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content